Increased risk of cardiovascular disease in Type 1 diabetes: Arterial exposure to remnant lipoproteins leads to enhanced deposition of cholesterol and binding to glycated extracellular matrix proteoglycans

Diabetic Medicine

Volumn 28, Issue 1, 2011, Pages 61-72

  Mangat, R ^a   Su, J W ^a   Lambert, J E ^a   Clandinin, M T ^a   Wang, Y ^a   Uwiera, R R ^a   Forbes, J M ^b   Vine, D F ^a   Cooper, M E ^b   Mamo, J C ^c   Proctor, S D ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Atherosclerosis; Chylomicrons; Diabetes; Lipoproteins

Indexed keywords

APOLIPOPROTEIN B48; BIGLYCAN; CHOLESTEROL; LIPOPROTEIN; PROTEOGLYCAN; STREPTOZOCIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTERY PERFUSION; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; EX VIVO STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIPOPROTEIN METABOLISM; MALE; NONHUMAN; RAT;

ANIMALS; APOLIPOPROTEIN B-48; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL; DIABETES MELLITUS, TYPE 1; EXTRACELLULAR MATRIX; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PROTEOGLYCANS; RATS; RATS, INBRED STRAINS; RISK FACTORS;

EID: 78650244298     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.03138.x     Document Type: Article

References (48)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. J Am Med Assoc 1979; 241: 2035-2038.
2. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987; 28: 613-628.
3. Tomkin GH, Owens D. Abnormalities in apoB-containing lipoproteins in diabetes and atherosclerosis. Diabetes Metab Res Rev 2001; 17: 27-43.
4. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Non-fasting triglycerides and risk of for myocardial infarction and death among women and men. Ugeskr Laeger 2007; 169: 3865-3868.
5. Meyer E, Westerveld HT, de Ruyter-Meijstek FC, van Greevenbroek MM, Rienks R, van Rijn HJ et al. Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: a case-control study. Atherosclerosis 1996; 124: 221-235.
6. Proctor SD, Vine DF, Mamo JC. Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis. Curr Opin Lipidol 2002; 13: 461-470.
7. Su JW, Lambert JE, Clandinin MT, Proctor SD. Impaired postprandial metabolism of apolipoprotein B48-containing remnant particles in normolipidemic subjects with brittle type 1 diabetes. Diabetes Care 2009; 32: e21.
8. Georgopoulos A, Phair RD. Abnormal clearance of postprandial Sf 100-400 plasma lipoproteins in insulin-dependent diabetes mellitus. J Lipid Res 1991; 32: 1133-1141.
9. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993; 143: 1649-1656.
10. Rabago Rodriguez R, Gomez-Diaz RA, Tanus Haj J, Avelar Garnica FJ, Ramirez Soriano E, Nishimura Meguro E et al. Carotid intima-media thickness in pediatric type 1 diabetic patients. Diabetes Care 2007; 30: 2599-2602.
11. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications participants with type 1 diabetes. Diabetes 2005; 54: 3103-3111.
12. Camejo G, Olsson U, Hurt-Camejo E, Baharamian N, Bondjers G. The extracellular matrix on atherogenesis and diabetes-associated vascular disease. Atheroscler Suppl 2002; 3: 3-9.
13. Dane-Stewart CA, Watts GF, Pal S, Chan D, Thompson P, Hung J et al. Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. Metabolism 2003; 52: 1279-1286.
14. Vine DF, Takechi R, Russell JC, Proctor SD. Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat: increased atherogenicity for the metabolic syndrome. Atherosclerosis 2007; 190: 282-290.
15. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G et al. The breakdown of pre-existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 2003; 17: 1762-1764.
16. Proctor SD, Mamo JC. Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 2003; 23: 1595-1600.
17. Proctor SD, Vine DF, Mamo JC. Arterial permeability and efflux of apolipoprotein B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confocal microscopy. Arterioscler Thromb Vasc Biol 2004; 24: 2162-2167.
18. Cooper ME, Thallas V, Forbes J, Scalbert E, Sastra S, Darby I et al. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia 2000; 43: 660-664.
19. Su JW, Nzekwu MM, Cabezas MC, Redgrave T, Proctor SD. Methods to assess impaired postprandial metabolism and the impact for early detection of cardiovascular disease risk. Eur J Clin Invest 2009; 39: 741-754.
20. McDonald TO, Gerrity RG, Jen C, Chen HJ, Wark K, Wight TN et al. Diabetes and arterial extracellular matrix changes in a porcine model of atherosclerosis. J Histochem Cytochem 2007; 55: 1149-1157.
21. De Man FH, Cabezas MC, Van Barlingen HH, Erkelens DW, de Bruin TW. Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: postprandial metabolism and relation to premature atherosclerosis. Eur J Clin Invest 1996; 26: 89-108.
22. Taskinen MR. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes 1992; 41: S12-17.
23. Georgopoulos A, Rosengard AM. Abnormalities in the metabolism of postprandial and fasting triglyceride-rich lipoprotein subfractions in normal and insulin-dependent diabetic subjects: effects of sex. Metabolism 1989; 38: 781-789.
24. Jensen MD, Caruso M, Heiling V, Miles JM. Insulin regulation of lipolysis in non-diabetic and IDDM subjects. Diabetes 1989; 38: 1595-1601.
25. Duez H, Lamarche B, Uffelman KD, Valero R, Cohn JS, Lewis GF. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler Thromb Vasc Biol 2006; 26: 1357-1363.
26. Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagne C, Couture P. Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes. J Lipid Res 2007; 48: 1336-1342.
27. Federico LM, Naples M, Taylor D, Adeli K. Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine. Diabetes 2006; 55: 1316-1326.
28. Young NL, McNamara DJ, Saudek CD, Krasovsky J, Lopez DR, Levy G. Hyperphagia alters cholesterol dynamics in diabetic rats. Diabetes 1983; 32: 811-819.
29. Young NL, Lopez DR, McNamara DJ. Contributions of absorbed dietary cholesterol and cholesterol synthesized in small intestine to hypercholesterolemia in diabetic rats. Diabetes 1988; 37: 1151-1156.
30. Proctor SD, Pabla CK, Mamo JC. Arterial intimal retention of pro-atherogenic lipoproteins in insulin-deficient rabbits and rats. Atherosclerosis 2000; 149: 315-322.
31. Olin-Lewis K, Krauss RM, La Belle M, Blanche PJ, Barrett PH, Wight TN et al. ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan. J Lipid Res 2002; 43: 1969-1977.
32. Heickendorff L, Ledet T, Rasmussen LM. Glycosaminoglycans in the human aorta in diabetes mellitus: a study of tunica media from areas with and without atherosclerotic plaque. Diabetologia 1994; 37: 286-292.
33. Wasty F, Alavi MZ, Moore S. Distribution of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and diabetes mellitus. Diabetologia 1993; 36: 316-322.
34. Nakashima Y, Fujii H, Sumiyoshi S, Wight TN, Sueishi K. Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arteriorscler Thromb Vasc Biol 2007; 27: 1159-1165.
35. O'Brien KD, Olin KL, Alpers CE, Chiu W, Ferguson M, Hudkins K et al. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation 1998; 98: 519-527.
36. Chait A, Wight TN. Interaction of native and modified low-density lipoproteins with extracellular matrix. Curr Opin Lipidol 2000; 11: 457-463.
37. Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417: 750-754.
38. Flood C, Gustafsson M, Pitas RE, Arnaboldi L, Walzem RL, Boren J. Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100. Arterioscler Thromb Vasc Biol 2004; 24: 564-570.
39. Batt KV, Avella M, Moore EH, Jackson B, Suckling KE, Botham KM. Differential effects of low-density lipoprotein and chylomicron remnants on lipid accumulation in human macrophages. Exp Biol Med (Maywood) 2004; 229: 528-537.
40. Batt KV, Patel L, Botham KM, Suckling KE. Chylomicron remnants and oxidised low density lipoprotein have differential effects on the expression of mRNA for genes involved in human macrophage foam cell formation. J Mol Med 2004; 82: 449-458.
41. Botham KM, Moore EH, De Pascale C, Bejta F. The induction of macrophage foam cell formation by chylomicron remnants. Biochem Soc Trans 2007; 35: 454-458.
42. Negre-Salvayre A, Salvayre R, Auge N, Pamplona R, Portero-Otin M. Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal 2009 Dec; 11: 3071-3109.
43. Jandeleit-Dahm K, Cooper ME. The role of AGEs in cardiovascular disease. Curr Pharm Des 2008; 14: 979-986.
44. Brownlee M, Vlassara H, Cerami A. Non-enzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes 1985; 34: 938-941.
45. Reigle KL, Di Lullo G, Turner KR, Last JA, Chervoneva I, Birk DE et al. Non-enzymatic glycation of type I collagen diminishes collagen-proteoglycan binding and weakens cell adhesion. J Cell Biochem 2008; 104: 1684-1698.
46. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 2002; 99: 15596-15601.
47. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101.
48. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem 1995; 270: 10828-10832.